The news at a glance

Apple: Steve Jobs’ liver transplant; Autos: GM finds a buyer for Saab; Pharmaceuticals: Novartis treatment approved; Investigations: Stanford indicted; Retailing: Eddie Bauer treks to bankruptcy court

Apple: Steve Jobs’ liver transplant

Apple CEO Steve Jobs, on medical leave from the company since January, underwent a liver transplant in April, said Yukari Iwatani Kane and Joann Lublin in The Wall Street Journal. He is still scheduled to return to work at the end of June, “though he may work part time initially.” Jobs, 54, was diagnosed in 2004 with a rare, treatable form of pancreatic cancer, which apparently had metastasized to his liver. Liver transplants for cancer sufferers are “controversial because livers are scarce and the surgery’s efficacy as a cure hasn’t been proved.” Jobs reportedly chose Tennessee “because its list of patients waiting for transplants is shorter than in many other states.”

Despite the initial fears of many Apple shareholders, the company has continued to prosper in Jobs’ absence, said Rex Crum in This week the company reported that it sold more than 1 million of its latest-generation iPhone within three days of the device’s launch. “Sales weren’t hurt by Apple doubling the storage capacity of the iPhone 3G S while keeping prices the same as earlier iPhone models.”

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.


Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

Autos: GM finds a buyer for Saab

General Motors has chosen Koenigsegg, “a tiny sports car company,” as the buyer for its Saab line of cars, said The Economist. The Saab brand, which once “appealed to discerning buyers who valued understated Swedish design and innovative technology,” had been tarnished under GM’s ownership. Koenigsegg, though, “is run by people who should understand the unique quirkiness of Saab’s appeal.” Owned by Swedish financier Christian von Koenigsegg, it currently “makes fewer than 20 cars a year, at a price of more than $1.2 million apiece.”

Pharmaceuticals: Novartis treatment approved

The Food and Drug Administration has approved Ilaris, a new drug developed by Novartis to treat a rare genetic disease, said Jeanne Whalen in The Wall Street Journal. Cryopyrin-associated periodic syndrome, or CAPS, “causes the body to overproduce interleukin-1, a protein tied to the immune system.” Only about 7,000 people worldwide suffer from CAPS, but despite Ilaris’ small market, it is “a big symbol of the way drug development is changing.” Rather than “bombarding” an illness with chemicals, Ilaris takes aim at the single gene that causes the painful disorder.

Investigations: Stanford indicted

Financier Allen Stanford was indicted last week for defrauding investors out of $7 billion, said Clifford Krauss in The New York Times. “The suspected fraud involved billions of dollars of certificates of deposit issued by Stanford International Bank, located on the Caribbean island of Antigua.” Although Stanford claimed the CDs were safe, conservative investments, authorities say that depositors’ money “was surreptitiously invested in real estate, other speculative investments, and into Stanford’s own operations.” Stanford has repeatedly declared his innocence.

Retailing: Eddie Bauer treks to bankruptcy court

Outdoor-clothing chain Eddie Bauer Holdings filed for Chapter 11 bankruptcy last week, said Steven Church in The company, which hasn’t reported a profit in three years, got into trouble after it was acquired by catalogue retailer Spiegel in 1988 and expanded from 61 stores to 501. Buyout firm CCMP Capital has offered to buy Eddie Bauer for $202 million, intending to “operate the business as a going concern with little or no long-term debt.”

Continue reading for free

We hope you're enjoying The Week's refreshingly open-minded journalism.

Subscribed to The Week? Register your account with the same email as your subscription.